AIM ImmunoTech

Hemispherx Biopharma
Entity Type
Founding Date

AIM ImmunoTech is a biotechnology company focused on the research and development of therapeutics to treat various cancers and immune-deficiency disorders. It has established a solid foundation of laboratory, pre-clinical and clinical data in relation to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body.



Ampligen® represents an RNA being developed for globally important cancers, viral diseases, and disorders of the immune system. It has demonstrated the potential for standalone efficacy in a number of solid tumors. It is also being used as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center. There are currently multiple Ampligen® clinical trials at major cancer research centers around the country.

Alferon N Injection®

Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina. It is the only natural-source, multi-species alpha-interferon currently approved for sale in the U.S. for the intralesional treatment of refractory or recurring external Condylomata Acuminata/genital warts in patients 18 years of age or older.

AIM ImmunoTech was formerly known as Hemispherx Biopharma.